Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteus Biomedical has initiated the Retime 2.0 study to assess the performance of the company's cardiac electric tomography and multi-sensor lead system for the measurement of cardiac performance in heart failure patients undergoing implantation of a cardiac resynchronization therapy device.
Subscribe to our email newsletter
Data from preclinical studies and from the company’s Retime 1.0 study demonstrated that cardiac electric tomography (CET) quantifies important aspects of cardiac performance using an automated, operator-independent technique that yields results comparable to Tissue Doppler Imaging.
The Retime 2.0 study will evaluate the system’s ability to provide immediate, actionable physiologic feedback to determine optimal pacing sites in individual patients by correlating CET data with left ventricular pressure catheter readings, the current gold standard for measuring hemodynamic performance.
The Retime 2.0 study will enroll a total of 30 patients at three sites: Ohio State University, with William Abraham and Ayesha Hasan serving as co-investigators; the University of Southern California, with Ray Matthews and Michael Cao as co-investigators; and Cardiocentro Ticino in Lugano, Switzerland, with Angelo Auricchio as investigator.